eMedicine Specialties > Radiology > Genitourinary
Prostate Carcinoma: Multimedia
Updated: Apr 18, 2007
Multimedia
 | Media file 1: Axial transrectal ultrasonographic (TRUS) scan shows extensive hypoechoic area (arrows) in the right peripheral zone. Biopsy revealed prostatic adenocarcinoma. |
 | Media file 2: Axial transrectal ultrasonographic (TRUS) scan shows a hypoechoic area in left peripheral zone and a small hypoechoic area in right peripheral zone (arrows). Biopsy revealed an adenocarcinoma (Gleason grade 6). |
 | Media file 3: Axial transrectal sonogram in a patient with normal results during digital rectal examination and a prostate-specific antigen (PSA) level of 9 ng/mL. Image shows extensive bilateral but predominantly left-sided hypoechoic areas in the peripheral zone (arrows). Biopsy confirmed a Gleason grade 8 prostate cancer. Minor capsular irregularity is present on the left; this is consistent with a T3 tumor. |
 | Media file 4: Axial transrectal ultrasonographic (TRUS) power Doppler scan in the same patient as in Image 3. The patient had normal results with digital rectal examination and a prostate-specific antigen (PSA) level of 9 ng/mL. A generalized increase in vascularity was noted in the posterior aspect of the prostate (arrows). However, this finding is not specific to the hypoechoic area in the left peripheral zone, illustrating the difficulty of using Doppler techniques in the assessment of prostate cancer. |
 | Media file 5: Axial transrectal ultrasonographic (TRUS) scan in a patient with clinical benign prostatic hyperplasia (BPH) and a serum prostate-specific antigen (PSA) level of 11 ng/mL. Enlargement of the transition zone is present, but no focal abnormality is observed in the peripheral zone. Systematic 6-core biopsy revealed adenocarcinoma from both lobes of the prostate (ie, this is an isoechoic tumor in the peripheral zone of both prostatic lobes). |
 | Media file 6: Sonogram shows an extensive, hypoechoic T3 tumor (arrowheads). Capsular irregularity is present, particularly on the right and posteriorly, with a suggestion of infiltration into the rectal wall (arrow). |
 | Media file 7: Coronal T2-weighted magnetic resonance image (MRI) study of the prostate gland obtained by using an external coil. Low signal intensity (arrow) is seen on the left side of the prostate at the site of a biopsy-proven prostate cancer. |
 | Media file 8: Endorectal magnetic resonance imaging in a patient with extensive prostate carcinoma. Image shows a bulge in the capsular outline on the right side (arrow). This is a stage T3 tumor. |
 | Media file 9: Endorectal axial T2-weighted magnetic resonance imaging in a patient with a prostate-specific antigen level of 8 ng/mL and right-sided prostate cancer. Low signal intensity is demonstrated in the right peripheral zone (arrow). |
 | Media file 10: Patient with biopsy-proven prostate cancer. Axial T1-weighted magnetic resonance imaging of the pelvis shows an enlarged left obturator node (arrow). |
 | Media file 11: Isotope bone scans show multiple areas of increased tracer activity from metastatic prostate cancer. |
 | Media file 12: Isotopic bone scans. Diffuse metastases demonstrate a superscan appearance. Note that no renal excretion of radioactive tracer is demonstrated. |
 | Media file 13: Pelvic radiograph shows widespread osteoblastic sclerotic metastases from prostate cancer. |
 | Media file 14: Axial computed tomography (CT) scan at the level of the kidneys shows extensive para-aortic lymphadenopathy (arrows), which result from advanced prostate cancer |
 | Media file 15: Metastatic prostate cancer (arrows) involves the soft tissues at the right side of the skull base. The patient presented with right-sided cranial nerve XII palsy. |
More on Prostate Carcinoma |
| Overview: Prostate Carcinoma |
| Imaging: Prostate Carcinoma |
| Follow-up: Prostate Carcinoma |
 Multimedia: Prostate Carcinoma |
| References |
| « Previous Page |
References
Noguchi M, Stamey TA, Neal JE, Yemoto CE. An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics. J Urol. Jun 2000;163(6):1751-5.
Sobin LH, Wittekind CL, eds. TNM Classification of Malignant Tumors. 6th ed. New York, NY: John Wiley & Sons;2002.
Jemal A, Siegel R, Ward E. Cancer statistics, 2006. CA Cancer J Clin. Mar-Apr 2006;56(2):106-30.
McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol. Dec 1988;12(12):897-906. [Medline].
Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. Aug 18 1993;270(7):860-4. [Medline].
Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet. Nov 1993;13;342(888):1209-10.
Morton MS, Turkes A, Denis L, Griffiths K. Can dietary factors influence prostatic disease?. BJU Int. Sep 1999;84(5):549-54.
Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. Jun 19 2003;348(25):2491-9. [Medline].
Rosenthal SA, Haseman MK, Polascik TJ. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. Tech Urol. Mar 2001;7(1):27-37.
Benson MC, Whang IS, Pantuck A, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. Mar 1992;147(3 Pt 2):815-6. [Medline].
Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. May 20 1998;279(19):1542-7. [Medline].
Clements R. Contemporary ultrasound guided biopsy in the diagnosis of prostate cancer. Imaging. 2001;13:18-26.
Clements R. Prostate specific antigen: an opinion on its value to the radiologist. Eur Radiol. 1999;9(3):529-35. [Medline].
Eskew LA, Woodruff RD, Bare RL, McCullough DL. Prostate cancer diagnosed by the 5 region biopsy method is significant disease. J Urol. Sep 1998;160(3 Pt 1):794-6. [Medline].
Even-Sapir E, Metser U, Mishani E. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. Feb 2006;47(2):287-297.
Halpern EJ, Rosenberg M, Gomella LG. Prostate cancer: contrast-enhanced us for detection. Radiology. Apr 2001;219(1):219-25. [Medline].
Hata N, Jinzaki M, Kacher D, et al. MR imaging-guided prostate biopsy with surgical navigation software: device validation and feasibility. Radiology. Jul 2001;220(1):263-8. [Medline].
Huch Boni RA, Boner JA, Debatin JF, et al. Optimization of prostate carcinoma staging: comparison of imaging and clinical methods. Clin Radiol. Sep 1995;50(9):593-600. [Medline].
Kirby R, Christmas T, Brawer MK. Prostate Cancer. 2nd ed. St Louis: Mosby-Year Book;2001.
Lavoipierre AM, Snow RM, Frydenberg M, et al. Prostatic cancer: role of color Doppler imaging in transrectal sonography. AJR Am J Roentgenol. Jul 1998;171(1):205-10. [Medline].
Lawrentschuk N, Davis ID, Bolton DM. Positron emission tomography and molecular imaging of the prostate: an update. BJU Int. May 2006;97(5):923-31.
Mettlin C, Chesley AE, Murphy GP, et al. Association of free PSA percent, total PSA, age, and gland volume in the detection of prostate cancer. Prostate. May 15 1999;39(3):153-8. [Medline].
Padhani AR, Gapinski CJ, Macvicar DA, et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol. Feb 2000;55(2):99-109. [Medline].
Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. May 14 1997;277(18):1445-51. [Medline].
Presti JC Jr, Hricak H, Narayan PA, et al. Local staging of prostatic carcinoma: comparison of transrectal sonography and endorectal MR imaging. AJR Am J Roentgenol. Jan 1996;166(1):103-8. [Medline].
Reske SN, Blumstein NM, Neumaier B. Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med. Aug 2006;47(8):1249-54.
Rifkin MD. Ultrasound of the Prostate. 2nd ed. Philadelphia: Lippincott, Williams & Wilkins;1996.
Sandblom G, Sörensen J, Lundin N. Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology. May 2006;67(5):996-1000.
Siegelman ES. Magnetic resonance imaging of the prostate. Semin Roentgenol. Oct 1999;34(4):295-312. [Medline].
Terris MK. The appearance of adenoid cystic carcinoma of the prostate on transrectal ultrasonography. BJU Int. May 1999;83(7):875-6.
Ukimura O, Troncoso P, Ramirez EI, Babaian RJ. Prostate cancer staging: correlation between ultrasound determined tumor contact length and pathologically confirmed extraprostatic extension. J Urol. Apr 1998;159(4):1251-9. [Medline].
Wachter S, Tomek S, Kurtaran A, et al. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol. Jun 1 2006;24(16):2513-9.
Whitmore WF Jr. Localised prostatic cancer: management and detection issues. Lancet. May 21 1994;343(8908):1263-7. [Medline].
Wong TZ, Turkington TG, Polascik TJ, Coleman RE. ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology. AJR Am J Roentgenol. Feb 2005;184(2):676-80.
Yu KK, Scheidler J, Hricak H, et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology. Nov 1999;213(2):481-8. [Medline].
Further Reading
Keywords
prostate carcinoma, prostatic cancer, prostatic carcinoma, prostatic adenocarcinoma, prostatic intraepithelial neoplasia, PIN, prostate-specific antigen, PSA, digital rectal examination, DRE, comedocarcinoma
